南アフリカの思春期の少女と若い女性を HIV ワクチンの誤った情報から守る (PROTECT)
Adolescent girls and young women (AGYW) between the ages of 15-29 years continue to bear the brunt of Human Immunodeficiency Virus (HIV) infections in South Africa despite progress recorded in prevention and treatment programmes. The ongoing susceptibility of young women to HIV infection and the sub-optimal uptake of prevention options such as Pre-Exposure Prophylaxis (PrEP) that are highly effective creates a need for an HIV vaccine to benefit populations at substantial risk of HIV infection. However, lessons from previous vaccine studies and the recent COVID-19 vaccine have highlighted significant barriers to vaccine uptake, such as widespread misinformation and vaccine hesitancy. These challenges threaten the successful implementation of a future HIV vaccine. Building on these insights, this study will utilise psychological inoculation theory to develop and evaluate HIV vaccine messages among adolescent girls and young women. Primary objective: To compare changes in intentions to receive HIV vaccine following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.
Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about the HIV vaccine in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Johannesburg、南アフリカ
- Health Economics and Epidemiology Research Office, University of the Witwatersrand
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Female
- Age 18-29 years
- Self-reported history of sexual activity in the past 12 months
- Self-reported HIV-negative status or unknown HIV status at enrolment
- Willing and able to provide written informed consent
- Able to read and understand English
Exclusion Criteria:
- Unwilling or unable to provide consent for study participation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Control
Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study. |
Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study. |
|
他の:Enhanced inoculation message
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. |
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
HIV Vaccine Intention, at the End of the Baseline Assessment
時間枠:At the end of the baseline assessment
|
Intention to get the HIV vaccine, measured after inoculation intervention and misinformation exposure The intention to get the vaccine will be measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine. |
At the end of the baseline assessment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
HIV Vaccine Intention, Follow-up
時間枠:2-4 weeks
|
Intention to get the HIV vaccine, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine. |
2-4 weeks
|
|
Recommend to Friends, at the End of the Baseline Assessment
時間枠:At the end of the baseline assessment
|
Intention to recommend the HIV vaccine to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend. |
At the end of the baseline assessment
|
|
Recommend to Friends, Follow-up
時間枠:2-4 weeks
|
Intention to recommend the HIV vaccine to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend. |
2-4 weeks
|
|
Credibility of Inoculated Exposure #1
時間枠:At the end of the baseline assessment
|
Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #2
時間枠:At the end of the baseline assessment
|
Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #3
時間枠:At the end of the baseline assessment
|
Extent to which claim #3 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #4
時間枠:At the end of the baseline assessment
|
Extent to which claim #4 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #5
時間枠:At the end of the baseline assessment
|
Extent to which claim #5 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #6
時間枠:At the end of the baseline assessment
|
Extent to which claim #6 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #1
時間枠:At the end of the baseline assessment
|
Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #2
時間枠:At the end of the baseline assessment
|
Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #3
時間枠:At the end of the baseline assessment
|
Extent to which claim #3 made the participants anxious or nervous about the HIV vaccine. TThey were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #4
時間枠:At the end of the baseline assessment
|
Extent to which claim #4 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #5
時間枠:At the end of the baseline assessment
|
Extent to which claim #5 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #6
時間枠:At the end of the baseline assessment
|
Extent to which claim #6 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #1
時間枠:At the end of the baseline assessment
|
Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #7
時間枠:At the end of the baseline assessment
|
Extent to which claim #7 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #3
時間枠:At the end of the baseline assessment
|
Extent to which claim #3 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #4
時間枠:At the end of the baseline assessment
|
Extent to which claim #4 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #5
時間枠:At the end of the baseline assessment
|
Extent to which claim #5 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #6
時間枠:At the end of the baseline assessment
|
Extent to which claim #6 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #1, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of Inoculated Exposure #2, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Shareability of Inoculated Exposure #1, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of Inoculated Exposure #2, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Anxiousness of Inoculated Exposure #1, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of Inoculated Exposure #2, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #12, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #12 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #8, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #8 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #9, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #9 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #10, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #10 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #11, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #11 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Anxiousness o of New Claims, Exposure #12, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #12 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Claim #8, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #8 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #9, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #9 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #10, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #10 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #11, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #11 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #12, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #12 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #8, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #8 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #9, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #9 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #10, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #10 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #11, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #11 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Credibility of Inoculated Exposure #7
時間枠:At the end of the baseline assessment
|
Extent to which claim #7 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #7
時間枠:At the end of the baseline assessment
|
Extent to which claim #7 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #2
時間枠:At the end of the baseline assessment
|
Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Credibility of New Claims, Exposure #13, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #13 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #13, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #13 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #13, Follow-up
時間枠:2-4 weeks
|
Extent to which claim #13 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 1R01MH132401 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The investigators are still determining the data sharing plan and if we will be sharing IPD yet
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。